Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05143840
Title Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase (ALERTCML)
Acronym ALERTCML
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Augusta University
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Georgia Cancer Center at Augusta University RECRUITING Augusta Georgia 30912 United States Details
Karmanos Cancer Institute RECRUITING Detroit Michigan 48201 United States Details
Roswell Park Comprehensive Cancer Center RECRUITING Buffalo New York 14263 United States Details
Memorial Sloan Kettering Cancer Center RECRUITING New York New York 10065 United States Details
Huntsman Cancer Institute RECRUITING Salt Lake City Utah 84112 United States Details
Froedtert Hospital & the Medical College of Wisconsin RECRUITING Milwaukee Wisconsin 53226 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field